Sandoz Group AG, founded in 1886 and headquartered in Holzkirchen, Germany, is a global leader in the pharmaceutical industry, specializing in generic and biosimilar medicines designed to enhance patient access to essential healthcare. The company offers a diverse portfolio of high-quality, cost-effective pharmaceuticals, addressing various therapeutic areas such as oncology, cardiology, and immunology.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| SDZSW 1.25% 2028-03-31 CHFSandoz Group AG | Switzerland | 2028-03-31 | 1.250 | 0.62 |
| SDZSW 2.13% 2026-11-17 CHFSandoz Group AG | Switzerland | 2026-11-17 | 2.125 | 0.39 |
| SDZSW 2.60% 2031-11-17 CHFSandoz Group AG | Switzerland | 2031-11-17 | 2.600 | 1.12 |
| SDZSW 4.22% 2030-04-17 EURSandoz Group AG | Switzerland | 2030-04-17 | 4.220 | 3.01 |
| SDZSW 4.50% 2033-11-17 EURSandoz Group AG | Switzerland | 2033-11-17 | 4.500 | 3.58 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Sandoz has been an active bond issuer since 2015, with notable issuances including a €500 million bond in 2020 aimed at refinancing and supporting strategic initiatives. The company’s bonds are characterized by their strong credit ratings and competitive yields, often outperforming industry averages. Recent news highlights a €600 million sustainability-linked bond issued in 2022, connecting financing to Sandoz's commitment to environmental sustainability and responsible sourcing.